{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:01:53Z","timestamp":1784808113148,"version":"3.55.0"},"reference-count":24,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,4,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Although second-generation tyrosine kinase inhibitors (TKIs) show superiority in achieving deep molecular responses in chronic myeloid leukemia in chronic phase (CML-CP) compared with imatinib, the differing adverse effect (AE) profiles need consideration when deciding the best drug for individual patients. Long-term data from randomized trials of nilotinib demonstrate an increased risk of vascular AEs (VAEs) compared with other TKIs, although the natural history of these events in response to dose modifications or cessation has not been fully characterized. We retrospectively reviewed the incidence of nilotinib-associated AEs in 220 patients with CML-CP at 17 Australian institutions. Overall, AEs of any grade were reported in 95 patients (43%) and prompted nilotinib cessation in 46 (21%). VAEs occurred in 26 patients (12%), with an incidence of 4.1 events per 100 patient-years. Multivariate analysis identified age (P = .022) and dyslipidemia (P = .007) as independent variables for their development. There was 1 fatal first VAE, whereas the remaining patients either continued nilotinib (14 patients) or stopped it immediately (11 patients). Recurrent VAEs were associated with ongoing therapy in 7 of 14 who continued (with 2 fatal VAEs) vs 1 of 11 who discontinued (P = .04). Nineteen of the 23 evaluable patients surviving a VAE ultimately stopped nilotinib, of whom 14 received an alternative TKI. Dose reduction or cessation because of VAEs did not adversely affect maintenance of major molecular response. These findings demonstrate that in contrast to other AEs, VAEs are ideally managed with nilotinib cessation because of the increased risk of additional events with its ongoing use.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018028035","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T17:53:51Z","timestamp":1554314031000},"page":"1084-1091","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7357-2024","authenticated-orcid":false,"given":"Adrian G.","family":"Minson","sequence":"first","affiliation":[{"name":"Department of Clinical Haematology, Austin Hospital, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Cummins","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Austin Hospital, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Fox","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Austin Hospital, Melbourne, Australia;"},{"name":"Peter MacCallum Cancer Centre, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Costello","sequence":"additional","affiliation":[{"name":"Baker IDI Heart and Diabetes Institute, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Yeung","sequence":"additional","affiliation":[{"name":"Royal Adelaide Hospital, Adelaide, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Cleary","sequence":"additional","affiliation":[{"name":"Princess Alexandra Hospital, Brisbane, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecily","family":"Forsyth","sequence":"additional","affiliation":[{"name":"Gosford Hospital, Gosford, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciek","family":"Tatarczuch","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Burbury","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Motorna","sequence":"additional","affiliation":[{"name":"Monash Health, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Shortt","sequence":"additional","affiliation":[{"name":"Monash Health, Melbourne, Australia;"},{"name":"School of Clinical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Fleming","sequence":"additional","affiliation":[{"name":"Alfred Hospital, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"McQuillan","sequence":"additional","affiliation":[{"name":"Hollywood Medical Centre, Perth, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Schwarer","sequence":"additional","affiliation":[{"name":"Box Hill Hospital, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Harrup","sequence":"additional","affiliation":[{"name":"Royal Hobart Hospital, Hobart, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Holmes","sequence":"additional","affiliation":[{"name":"Canberra Hospital, Canberra, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumita","family":"Ratnasingam","sequence":"additional","affiliation":[{"name":"Royal Melbourne Hospital, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kah-Lok","family":"Chan","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s Hospital, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hsun","family":"Hsu","sequence":"additional","affiliation":[{"name":"Royal Prince Alfred Hospital, Sydney, Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Ashraf","sequence":"additional","affiliation":[{"name":"Calvary Mater Hospital, Newcastle, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faye","family":"Putt","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Austin Hospital, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Grigg","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Austin Hospital, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,4,3]]},"reference":[{"issue":"5","key":"2020021108275179900_B1","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"2020021108275179900_B2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.leukres.2017.05.008","article-title":"Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML","volume":"59","author":"Valent","year":"2017","journal-title":"Leuk Res"},{"issue":"24","key":"2020021108275179900_B3","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"2020021108275179900_B4","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3324\/haematol.2014.104075","article-title":"Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia","volume":"99","author":"Rea","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"2020021108275179900_B5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12185-012-1222-7","article-title":"Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin","volume":"97","author":"Ito","year":"2013","journal-title":"Int J Hematol"},{"issue":"17","key":"2020021108275179900_B6","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djr292","article-title":"Severe peripheral arterial disease during nilotinib therapy","volume":"103","author":"Le Coutre","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"2020021108275179900_B7","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am J Hematol"},{"key":"2020021108275179900_B8","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1182\/asheducation-2017.1.110","article-title":"Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy","volume":"2017","author":"Barber","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"suppl 2","key":"2020021108275179900_B9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/imj.13716","article-title":"Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors","volume":"48","author":"Ross","year":"2018","journal-title":"Intern Med J"},{"issue":"3","key":"2020021108275179900_B10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/M15-2306","article-title":"Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: A population-based cohort study","volume":"165","author":"Dahl\u00e9n","year":"2016","journal-title":"Ann Intern Med"},{"issue":"6","key":"2020021108275179900_B11","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3109\/10428194.2015.1091929","article-title":"Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis","volume":"57","author":"Chai-Adisaksopha","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2020021108275179900_B12","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"13","key":"2020021108275179900_B13","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/bloodadvances.2016003889","article-title":"The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia","volume":"1","author":"Fox","year":"2017","journal-title":"Blood Adv"},{"issue":"2","key":"2020021108275179900_B14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/bjh.14829","article-title":"Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd","volume":"179","author":"Hughes","year":"2017","journal-title":"Br J Haematol"},{"issue":"6","key":"2020021108275179900_B15","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2014-07-590315","article-title":"TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets","volume":"125","author":"Yeung","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2020021108275179900_B16","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1038\/leu.2017.247","article-title":"Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results","volume":"31","author":"Hughes","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"2020021108275179900_B17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00277-014-2231-9","article-title":"Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment","volume":"94","author":"Breccia","year":"2015","journal-title":"Ann Hematol"},{"issue":"21","key":"2020021108275179900_B18","article-title":"Identification of patients (pts) with chronic myeloid leukemia (CML) at high risk of artery occlusive events (AOE) during treatment with the 2nd generation tyrosine kinase inhibitor (TKI) nilotinib, using risk stratification for cardiovascular diseases (CVD) [abstract]","volume":"122","author":"Mirault","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2020021108275179900_B19","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/leu.2013.70","article-title":"Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib","volume":"27","author":"Kim","year":"2013","journal-title":"Leukemia"},{"issue":"22","key":"2020021108275179900_B20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.3068.3068","article-title":"Impact of age on efficacy, safety, and long-term outcome of chronic myeloid leukemia (CML) patients treated in first-line with nilotinib: an analysis of the gimema CML working party [abstract]","volume":"128","author":"Gugliotta","year":"2016","journal-title":"Blood"},{"key":"2020021108275179900_B21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.thromres.2016.07.019","article-title":"The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state","volume":"145","author":"Alhawiti","year":"2016","journal-title":"Thromb Res"},{"issue":"11","key":"2020021108275179900_B22","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1038\/leu.2017.245","article-title":"Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site","volume":"31","author":"Hadzijusufovic","year":"2017","journal-title":"Leukemia"},{"key":"2020021108275179900_B23","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.1016\/j.clml.2017.07.114","article-title":"Impact of arterial thrombotic events on the outcome of chronic myeloid leukemia patients treated with nilotinib first-line: a GIMEMA CML WP analysis [abstract]","volume":"17(suppl 2)","author":"Gugliotta","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"2020021108275179900_B24","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/7\/1084\/1631515\/advances028035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/7\/1084\/1631515\/advances028035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T08:46:34Z","timestamp":1581410794000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/7\/1084\/247280\/The-natural-history-of-vascular-and-other"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,3]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,4,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018028035","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,3]]}}}